Johnson & Johnson $JNJ Shares Sold by Cambiar Investors LLC

Key Points

• Cambiar Investors LLC significantly reduced its stake in Johnson & Johnson by 99.5%, selling 262,476 shares, and now holds only 1,340 shares worth $222,000.
• Other institutional investors have increased their positions in Johnson & Johnson, with Highline Wealth Partners LLC boosting its stake by 51.8%.
• Johnson & Johnson recently declared a quarterly dividend of $1.30 per share, resulting in an annualized dividend of $5.20 and a yield of 2.9%.

Cambiar Investors LLC decreased its position in shares of Johnson & Johnson (NYSE:JNJ - Free Report) by 99.5% during the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,340 shares of the company's stock after selling 262,476 shares during the period. Cambiar Investors LLC's holdings in Johnson & Johnson were worth $222,000 at the end of the most recent quarter.

Other hedge funds have also recently bought and sold shares of the company. Lantz Financial LLC raised its position in shares of Johnson & Johnson by 3.3% during the 1st quarter. Lantz Financial LLC now owns 11,974 shares of the company's stock worth $1,986,000 after acquiring an additional 377 shares in the last quarter. Sulzberger Capital Advisors Inc. acquired a new stake in shares of Johnson & Johnson during the 4th quarter worth about $453,000. Joel Isaacson & Co. LLC raised its position in shares of Johnson & Johnson by 3.5% during the 1st quarter. Joel Isaacson & Co. LLC now owns 74,132 shares of the company's stock worth $12,294,000 after acquiring an additional 2,526 shares in the last quarter. State of Wyoming raised its position in shares of Johnson & Johnson by 205,580.0% during the 4th quarter. State of Wyoming now owns 10,284 shares of the company's stock worth $1,487,000 after acquiring an additional 10,279 shares in the last quarter. Finally, Tokio Marine Asset Management Co. Ltd. raised its position in shares of Johnson & Johnson by 7.0% during the 1st quarter. Tokio Marine Asset Management Co. Ltd. now owns 73,350 shares of the company's stock worth $12,164,000 after acquiring an additional 4,816 shares in the last quarter. Institutional investors and hedge funds own 69.55% of the company's stock.

Johnson & Johnson Stock Performance

Shares of JNJ stock traded down $0.38 during midday trading on Monday, hitting $176.26. The company had a trading volume of 9,283,816 shares, compared to its average volume of 8,411,460. The company's 50 day simple moving average is $161.70 and its 200 day simple moving average is $158.60. Johnson & Johnson has a 52-week low of $140.68 and a 52-week high of $177.57. The stock has a market cap of $424.49 billion, a price-to-earnings ratio of 18.85, a PEG ratio of 2.25 and a beta of 0.41. The company has a debt-to-equity ratio of 0.50, a current ratio of 1.01 and a quick ratio of 0.76.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last announced its earnings results on Wednesday, July 16th. The company reported $2.77 earnings per share for the quarter, beating the consensus estimate of $2.68 by $0.09. The company had revenue of $23.74 billion for the quarter, compared to the consensus estimate of $22.85 billion. Johnson & Johnson had a return on equity of 32.49% and a net margin of 25.00%. The company's revenue was up 5.8% on a year-over-year basis. During the same period last year, the business posted $2.82 EPS. Research analysts anticipate that Johnson & Johnson will post 10.58 earnings per share for the current fiscal year.

Johnson & Johnson Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, September 9th. Stockholders of record on Tuesday, August 26th will be issued a $1.30 dividend. This represents a $5.20 annualized dividend and a dividend yield of 3.0%. The ex-dividend date of this dividend is Tuesday, August 26th. Johnson & Johnson's dividend payout ratio (DPR) is currently 55.61%.

Wall Street Analyst Weigh In

JNJ has been the topic of a number of research reports. Barclays raised their price target on Johnson & Johnson from $165.00 to $176.00 and gave the stock an "equal weight" rating in a research note on Thursday, July 17th. Guggenheim restated a "neutral" rating and set a $167.00 price target (up previously from $164.00) on shares of Johnson & Johnson in a research note on Thursday, July 17th. Morgan Stanley raised their price target on Johnson & Johnson from $171.00 to $176.00 and gave the stock an "equal weight" rating in a research note on Thursday, July 17th. UBS Group raised their price target on Johnson & Johnson from $180.00 to $190.00 and gave the stock a "buy" rating in a research note on Thursday, July 17th. Finally, Wall Street Zen downgraded Johnson & Johnson from a "strong-buy" rating to a "buy" rating in a research note on Friday, July 18th. Nine analysts have rated the stock with a hold rating, ten have given a buy rating and two have assigned a strong buy rating to the company. According to data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and an average price target of $174.50.

About Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.